Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02452424 · MORE INFO

Limitations, agreements, and source contact

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors · Source last updated 2020-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Enrollment for this study was terminated early for insufficient evidence of clinical efficacy. Some of the planned statistical analyses described in the protocol and Statistical Analysis Plan (SAP) were not performed.
point Of Contact
email
CTRinfo@dsi.com
organization
Daiichi Sankyo Inc.
phone
908-992-6400
title
Medical Director
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Enrollment for this study was terminated early for insufficient evidence of clinical efficacy. Some of the planned statistical analyses described in the protocol and Statistical Analysis Plan (SAP) were not performed.
point Of Contact
email
CTRinfo@dsi.com
organization
Daiichi Sankyo Inc.
phone
908-992-6400
title
Medical Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice